Limitations of a quantitative swollen and tender joint count to assess and monitor patients with rheumatoid arthritis
- PMID: 18937635
Limitations of a quantitative swollen and tender joint count to assess and monitor patients with rheumatoid arthritis
Abstract
A quantitative count of swollen and tender joints is a primary measure to assess patients with rheumatoid arthritis (RA), and is weighted of higher value than the other 5 Core Data Set measures in all indices in which it is included. However a number of limitations of the swollen and tender joint count have been described in the rheumatology literature, including poor reproducibility, with a requirement to be performed by the same observer at each visit; likelihood to improve with placebo treatment as much or more than the other 5 RA Core Data Set measures in clinical trials; similar or lower relative efficiencies than global and patient measures to document differences between active and control treatments in clinical trials; improvement over 5 years in clinical care, while joint damage and functional disability may progress; and lower sensitivity to detect inflammatory activity than ultrasound. Most visits to a rheumatologist do not include a formal quantitative joint count. It may be suggested that a careful qualitative joint count, supplemented by quantitative patient self-report questionnaire scores, may be more than adequate to monitor and document changes in patient status in busy clinical settings.
Similar articles
-
Joint counts to assess rheumatoid arthritis for clinical research and usual clinical care: advantages and limitations.Rheum Dis Clin North Am. 2009 Nov;35(4):713-22, v-vi. doi: 10.1016/j.rdc.2009.10.004. Rheum Dis Clin North Am. 2009. PMID: 19962615 Review.
-
An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from that of placebo as effectively as the American College of Rheumatology 20% response criteria (ACR20) or the Disease Activity Score (DAS) in a rheumatoid arthritis clinical trial.Arthritis Rheum. 2003 Mar;48(3):625-30. doi: 10.1002/art.10824. Arthritis Rheum. 2003. PMID: 12632413 Clinical Trial.
-
RAPID3, an index to assess and monitor patients with rheumatoid arthritis, without formal joint counts: similar results to DAS28 and CDAI in clinical trials and clinical care.Rheum Dis Clin North Am. 2009 Nov;35(4):773-8, viii. doi: 10.1016/j.rdc.2009.10.008. Rheum Dis Clin North Am. 2009. PMID: 19962621 Review.
-
Relative efficiencies of physician/assessor global estimates and patient questionnaire measures are similar to or greater than joint counts to distinguish adalimumab from control treatments in rheumatoid arthritis clinical trials.J Rheumatol. 2008 Feb;35(2):201-5. Epub 2007 Nov 15. J Rheumatol. 2008. PMID: 18050378 Clinical Trial.
-
Time to score quantitative rheumatoid arthritis measures: 28-Joint Count, Disease Activity Score, Health Assessment Questionnaire (HAQ), Multidimensional HAQ (MDHAQ), and Routine Assessment of Patient Index Data (RAPID) scores.J Rheumatol. 2008 Apr;35(4):603-9. Epub 2008 Mar 1. J Rheumatol. 2008. PMID: 18322993
Cited by
-
Total-Body 18F-FDG PET/CT in Autoimmune Inflammatory Arthritis at Ultra-Low Dose: Initial Observations.J Nucl Med. 2022 Oct;63(10):1579-1585. doi: 10.2967/jnumed.121.263774. Epub 2022 May 19. J Nucl Med. 2022. PMID: 35589405 Free PMC article.
-
Interrater reliability of RheuMetric checklist scales for physician global assessment, inflammation, damage and patient distress.Rheumatol Adv Pract. 2024 Nov 6;8(4):rkae137. doi: 10.1093/rap/rkae137. eCollection 2024. Rheumatol Adv Pract. 2024. PMID: 39660105 Free PMC article.
-
Do patients with juvenile idiopathic arthritis in clinical remission have evidence of persistent inflammation on 3T magnetic resonance imaging?Arthritis Care Res (Hoboken). 2012 Dec;64(12):1846-54. doi: 10.1002/acr.21774. Arthritis Care Res (Hoboken). 2012. PMID: 22740386 Free PMC article.
-
Determination of the minimally important difference (MID) in multi-biomarker disease activity (MBDA) test scores: impact of diurnal and daily biomarker variation patterns on MBDA scores.Clin Rheumatol. 2019 Feb;38(2):437-445. doi: 10.1007/s10067-018-4276-y. Epub 2018 Aug 29. Clin Rheumatol. 2019. PMID: 30159791
-
Autoantibodies and other serological markers in rheumatoid arthritis: predictors of disease activity?Clin Rheumatol. 2009 Oct;28(10):1127-34. doi: 10.1007/s10067-009-1223-y. Epub 2009 Jul 14. Clin Rheumatol. 2009. PMID: 19597699 Review.
Publication types
MeSH terms
LinkOut - more resources
Other Literature Sources
Medical